cbdMD Secures GRAS Status for 200 mg Daily Broad Spectrum CBD
YCBD•cbdMD completed a self-affirmed GRAS determination supporting safe consumption of up to 200 mg per day of its broad spectrum CBD for healthy adults. The conclusion, based on peer-reviewed studies in rodents, human volunteers and canines, distinguishes cbdMD’s safety profile and could drive product adoption in wellness and healthcare channels.
1. Self-Affirmed GRAS Determination Achieved
On July 7, 2026, cbdMD announced the completion of a self-affirmed Generally Recognized as Safe (GRAS) determination for up to 200 mg per day of its broad spectrum CBD in healthy adults. The determination, reviewed by an independent panel of expert toxicologists, defines a clear safety threshold for consistent consumer use.
2. Extensive Peer-Reviewed Safety Research
The GRAS determination builds on a comprehensive dossier of safety data, including subchronic oral toxicity and genotoxicity assessments, pharmacokinetic studies, a double-blind tolerability trial in healthy volunteers and a placebo-controlled study in canines. These studies, spanning 2022 to 2025, establish cbdMD’s formulations as rigorously tested and clinically supported.
3. Strategic Implications for Market Expansion
With CMS launching physician-guided access incentives and FDA signaling enforcement discretion for dietary-supplement-standard CBD, cbdMD’s science-backed safety position aligns with evolving regulations. The GRAS status equips the company to expand across direct-to-consumer, retail and healthcare channels, enhancing confidence among clinicians, partners and consumers.
